1. Home
  2. NXGL vs GNPX Comparison

NXGL vs GNPX Comparison

Compare NXGL & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

HOLD

Current Price

$0.18

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$3.38

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXGL
GNPX
Founded
1997
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.9M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
NXGL
GNPX
Price
$0.18
$3.38
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
★ $2.00
N/A
AVG Volume (30 Days)
138.0K
★ 146.5K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 24.00
N/A
EPS
★ N/A
N/A
Revenue
★ $11,421,000.00
N/A
Revenue This Year
$50.77
N/A
Revenue Next Year
$46.15
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 31.46
N/A
52 Week Low
$0.24
$0.16
52 Week High
$2.89
$12.97

Technical Indicators

Market Signals
Indicator
NXGL
GNPX
Relative Strength Index (RSI) 25.63 39.83
Support Level N/A $3.26
Resistance Level $0.38 $3.56
Average True Range (ATR) 0.03 0.24
MACD -0.00 0.03
Stochastic Oscillator 16.72 4.26

Price Performance

Historical Comparison
NXGL
GNPX

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: